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Abstract: The recommendations of the current guidelines and the position papers of professional
societies from the European Society of Cardiology/European Society of Cardiothoracic Surgeons (ESC),
the American College of Cardiology/American Heart Association/Society of Thoracic Surgeon (ACC/
AHA/STS) and American Association of Thoracic Surgeon (AATS) regarding management of patients with
valvular heart endocarditis were updated over the past decade. However, some of the recommendations
appear to contradict one another. Given the changing paradigms on how the disease manifests, our aim was
to review the respective guidelines and highlight these differences whilst drawing attention to the subsequent
studies from which they were derived. In particular, concerns regarding antibiotic prophylaxis and therapy,
imaging modality for diagnosis and follow-up, cerebrovascular sequalae and timing of surgery are appraised
in detail. We also identified the novel techniques used such as transcatheter therapies and advances in
imaging modalities used for diagnosis and treatment of this condition. The lack of randomised control trials
(RCTs) does raise several issues regarding applicability of findings in day-to-day practice. Therefore, the
focus of upcoming studies should be on clearly defined multicenter RCTs to provide more robust evidence
for the management and treatment of infective endocarditis as future guidelines will be based on the
outcomes of these trials.
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Introduction
The recommendations of the current guidelines and the
position papers of professional societies from the European
Society of Cardiology/European Society of Cardiothoracic
Surgeons (ESC), the American College of Cardiology/
American Heart Association/Society of Thoracic Surgeon
(ACC/AHA/STS) and American Association of Thoracic
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Surgeon (AATS) regarding management of patients
with valvular heart endocarditis were updated in 2014
(1,2), 2015 (3) and again in 2016 (4) and 2017 (5,6)
respectively. There are important differences within the
recommendations relating to the management of patients
with heart valve endocarditis (HVE), as with updated
evidence via the publication of several reports from
professional society recommendations. This study aims to
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Level (Quality) of Evidence

Class (Strength) of Recommendation

Class I (Strong)
Benefit>>> Risk
Class IIa (Moderate)
Benefit>> Risk
Class Ib (Weak)
Benefit>/= Risk
Class III: No Benefit
(Moderate)
Benefit= Risk
Class III : Harm
(Strong)
Risk > Benefit

No definite guidelines on
the surgical management
of Heart Valve
Endocarditis are available

The choice among the different
valve substitutes still remains
guided by surgeon’s personal
experience or preference

Level A
Level B-R
Randomized
Level B-NR
Non randomized
Level C-LD
Limited Data
Level C-EO
Expert Opinion

Treatment strategy should be guided
by a comprehensive evaluation of the
anatomopathological characteristics
of the lesions and tailored to patients
clinical profile

Figure 1 Class of recommendation (COR) and the level of evidence (LOE) that establishes the degree of choice for a treatment.

compare the recommendations by current guidelines and
the position papers of professional societies with regards
to management of patients with HVE. This review is
focused on the differences between the two guidelines
developed, by cardiologists and cardiac surgeons, and its
purpose is to summarize new data that addresses some of
the ongoing debates. The authors present the following
article in accordance with the Narrative Review reporting
checklist (available at http://dx.doi.org/10.21037/atm-203739).
Class of recommendation (COR) and level or
quality of evidence
The implementation of the COR and level of evidence
(LOE) for the clinical strategy, intervention, treatment
or diagnostic tests in patient care with HVE is generally
addressed in prophylaxis, diagnosis and management
which includes the choice of the best valve substitute
and the timing for surgery as well as the prevention of
complications.
The focus of the guidelines for the management of
patients with infectious disease of the heart valves is
represented by the diagnosis and management of adult
patients in whom the infection of the heart valve has
occurred. The field of HVE is rapidly progressing, with
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updated knowledge about the natural history of patients
with valvular endocarditis, diagnostic imaging advances
and improvements in catheter-based interventions
alongside standard surgery. Several randomized controlled
trials (RCTs) were highlighted in the guidelines,
specifically with regards to the results on the timeliness
of intervention, on the choice of antibiotic treatment and
prevention of neurological complications. The main areas
of change include indications for transcatheter aortic
valve replacement (TAVR), for sutureless and for better
management of patients with prosthetic valve endocarditis.
The evidence also highlights a significant variability in
HVE presentation and difficulty in establishing unequivocal
clinical practice. Indeed, the recommendations from
the position papers of professional societies are based
on observational cohort studies or few individual RCTs
rather than multicenter RCTs or patient-level combined
analysis of RCTs. Figure 1 denotes the COR and the LOE
that establishes the degree of choice for a treatment. It is
important to point out that COR and LOE are dictated
separately. When a recommendation is graded as Level C
it is not universally considered as a weak recommendation.
In fact, many of the therapeutic addresses that are given in
the guidelines and professional societies recommendations
originate from non-randomized studies. However, RCTs
provide clear consensus for the application of a treatment
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and therefore determine its effectiveness and safety
(Figure 1).
The literature is scarce on data from randomized studies
classified as LOE A that address a systematic approach
not only for the choice of ideal substitute for IE but also
with regards to the choice of prosthetic heart valve. It is
indisputable that the LOE is useful to orient the timing
and choices of the prosthetic heart valve in endocarditis.
Analyzing the guidelines, we can observe that 6.7% of
evidence by ACC/AHA (1,6) is Class I and 3% of ESC
(3,5) is Class IIa. The LOE B based on recommendations
is measured at 57% for ACC/AHA and 18% for ESC while
the LOE C based on recommendations is measured at
36.3% for ACC/AHA and to 79% for ESC guidelines
Controversies regarding management of patients
with HVE
Effects of changing guidelines on the incidence of IE
In the case of IE, the AHA/ACC guidelines for antibiotic
prophylaxis are restrictive in the United States. Prophylaxis
is indicated in patients who have received a prosthetic valve,
CHD with an episode of IE, or in recipients of cardiac
transplantation in whom valvulopathy has developed (7).
DeSimone et al. (8,9), using data from the Rochester
Epidemiological Project, analyzed the incidence of IE due
to viridans group streptococci before and after the change
of prophylaxis guidelines. The authors found no significant
increase in the incidence and, in contrast, emphasized a
decrease of 3.6 per 100,000/year from 1999 to 2002 to
1.5 per 100,000 person-years from 2011–2013. Similarly,
two reports performed on the Canadian population (10)
and the United States (11) who underwent prophylactic
treatment for IE, found no evidence for a change point in
the incidence of IE to coincide with modified ACC/AHA
guidelines. The most relevant studies that contrast with
AHA/ACC are two national epidemiological studies from
the United States and the United Kingdom which raised
some concerns.
Pant et al. (12), using the Nationwide Inpatient Sample,
revealed that although they showed a statistically significant
increase in the incidence of IE caused by streptococci, they
were unable to identify significant changes in the trend,
with a growing curve, both in total admissions and in the
number of patients with IE due to S aureus. It should be
noted that this study included non-homogeneous groups
because of the incidence calculations in which both groups,
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non-viridans streptococci and enterococci were evaluated.
The weakness lies in the fact that the new change point
analysis was not carried out to confirm that the change in
the rate coincided with the ACC/AHA amended guidelines.
In addition, the investigators did not have access to the
prescription data of antibiotic prophylaxis to confirm that
this rate had decreased.
In the UK (13) there is a marked restriction on the use
of antibiotic prophylaxis. The national stance, since March
2008, is to advise against the use of antibiotic prophylaxis.
Initial analysis did not report an increase in the incidence
of IE. The effects of the restriction on the use of antibiotics
in IE prophylaxis are published in a 2015 study (14). In an
extended analysis, the hospital discharge diagnoses were
examined and reported by the National Health Service
until 2013. Antibiotic prophylaxis decreased from 10,900
prescriptions per month to 2,236 prescriptions per month
after the introduction of the UK National Institute for
Health and Care Excellence (NICE) guidelines. In parallel,
there was a significant increase (above the expected trend)
in the number of cases of IE, of 0.11 cases per 10 million
people (or another 35 cases in England) per month. The
statistical analysis identified June 2008 (3 months after
the implementation of the new guidelines for the use of
antibiotic prophylaxis) as a point of change, but it was
not possible to confirm that these cases were due to oral
streptococci because the microbiological data was not
available.
A large restriction on the use of antibiotic prophylaxis
for IE emerges from data from studies in France, where
antibiotic prophylaxis was limited to high risk groups as
early as 2002. The analysis used a very precise investigative
approach to collect data on all cases of IE in different
regions (15,16). The two studies showed that the incidence
of IE in three years of investigation (1991, 1999 and 2008)
was stable at 35, 33 and 32 cases per million, suggesting that
there was no significant change since the limitation of oral
antibiotic prophylaxis. Importantly, the number of cases
caused by oral streptococci was also stable. These data are
mainly established on the basis of large observational studies
and have not reported a causal link between restriction
of antibiotic prophylaxis and incidence of IE. One of
the reasons that causes a confusion is that the inferior
clinical results associated with reduced use of antibiotic for
prophylaxis of IE that have been reported in the registries
have not been replicated in RCTs. There is growing
concern that observational studies can be biased in favor of
an increase in the number of IE after implants of the device,
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although this factor has been adapted in some studies, by
unmatched confounders related to the unmeasurable (and
un-matchable) judgment of the operating cardiologist.
Despite long-term controversy and difficulties with
observational data, randomized trials are highly unlikely
due to cost, logistics, and ethical debate about real equipoise
exists to allow the conduction of a placebo-controlled study.
Currently the ACC/AHA (1) and the European Society
of Cardiology (ESC) (3,5,17) have a pragmatic approach in
which the indications are to limit prophylaxis to individuals
at higher risk based on their underlying heart conditions.
We believe that this approach represents a correct
balance between the risks and benefits for the individual
and the population of using antibiotics. It is important
to note that the indications do not include patients who
present with non-cardiac risk factors (e.g., those who are
immunodeficient) and who may be at increased risk of
IE and poor outcome if the disease develops. There is an
emergence of data that suggests in these patients, a tailored
approach to individual patients remains appropriate,
according to clinical circumstance (18,19).
Routine imaging
It is agreed that early pre-operative imaging is
recommended in all patients to establish a baseline for the
diagnosis and treatment of infective endocarditis. There is
a general consensus to the use of echocardiography, that
remains an effective and rapid method of imaging, which in
many cases is diagnostic (1,3,5,6,17) and graded as COR Ia
LOE: B both in ESC and AHA/ACC guidelines. However,
it should be emphasized that up to 30% of patients with
proven IE subsequently are labelled as “possible“ due to
negative or equivocal results on echocardiography or blood
cultures (20,21). The use of transthoracic echocardiography
(TTE) in early stage of diagnosis is the method of imaging
recommended in the patient with the suspicion of an
infectious endocarditis involving either a native valve
(NVE) or a prosthetic valve (PVE). In patients with NVE,
TTE has a sensitivity between 50% and 90%, while the
specificity reaches 90%. For suspected PVE, the use of
TTE has a lower sensitivity, ranging between 40% and
70%. However, it provides important information in the
assessment of ventricular size and on its function. The TTE
adds an additional evaluation on hemodynamic severity of
valve lesions, diagnosis of anterior prosthetic aorta valve
abscesses, which can be difficult to visualize with the use
of transoesophageal echocardiography (TEE). The use of
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TEE is indicated when the TTE is positive but it was not
sufficient to reach a diagnosis of infectious endocarditis,
when intracardiac complications are suspected or when
cables of an implantable device are present. In patients
with a suspected NVE, the TEE has a sensitivity from
90% to 100% and specificity of 90% for the detection
of vegetations and is superior to TTE for detection of
complications, such as perforations, abscesses, and fistula. In
ESC guidelines (3,5) TTE should be considered in patients
with suspected IE, even in cases with positive TTE, except
in isolated right-sided native valve IE with good quality
TTE examination and unequivocal echocardiographic
findings (COR IIa; LOE: C).
Concerns relating to precise diagnosis of PVE still
persist. In a recent meta-analysis, a reduced aggregate
sensitivity of 86% was shown [95% confidence interval (CI):
from 77% to 92%] for TEE in conferring a certainty for the
diagnosis of IE (22). As such, other imaging modalities are
emerging to help to make or exclude the diagnosis in cases
where TEE is not diagnostic. Even when abnormalities are
detected, it can be difficult to differentiate the presence of
nodules from small vegetations or to distinguish signs of
infection from tissue changes that occurred in the postoperative period. The use of cardiac computed tomography
(CT) scanning has established itself as the key additional
modality to be used when echocardiography does not
provide clearly delineated anatomy information. The CT
scanning has earned a recommendation to Class II, LOE: B
for use in IE in ACC/AHA 2014 guidelines for heart disease
(1,6). Compared to TEE, cardiac CT can be considered
equivalent or even superior to TEE to demonstrate precise
features of anatomy and paravalvular complications such as
paravalvular abscesses or mycotic aneurysms. In addition,
it is less prone to artifact compared to echocardiography in
the evaluation of prosthetic valves. The use of concomitant
CT angiography has become common practice because
this approach greatly assists surgical strategy planning.
Its wide use allows the exclusion of a significant coronary
artery disease in younger patients who can avoid coronary
angiography. Detection of para-valvular lesions using CT
imaging is now an important diagnostic criterion in the
ESC 2015 guidelines (3) on IE despite not yet reaching a
precise COR and LOE.
New evidence
A large consensus for the diagnosis of IE has occurred with
the use of combination of CT imaging with metabolic
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imaging by 18-fluorodeoxyglucose positron emission
tomography ( 18 FDG-PET) or leukocyte scintigraphy
(radiolabeled leukocyte single-photon emission computed
tomography (SPECT). This method is very promising
because it allows visualisation of regions with metabolic
activity or inflammation in patients who, according to the
Duke criteria, have “possible” IE or suspected of cardiac
device infection. Several reports have demonstrated the
effectiveness of this method. One study (23) evaluated the
effect of 18 FDG-PET in 72 patients who had suspected
PVE reporting diagnosis with an overall sensitivity of 73%
and a specificity of 80%. The patients who were managed
with 18FDG-PET as the additional criterion of “abnormal
prosthetic valve 18FDG-PET signal” showed an increased
sensitivity of the modified Duke criteria from 70% to 95%
thus reducing the number of patients with “possible IE”
from 56% to 32%. In another report (24), 76 of 92 patients
with suspected PVE or CDI were studied using 18FDGPET/CT (angiography), CT and echocardiography
providing a conclusive diagnosis in 95% of cases overall.
The addition of this procedure has been associated with
greater general sensitivity and specificity ranging between
87% and 90%, respectively, and an increased sensitivity of
the modified Duke criteria from 51% to 91%.
Leukocyte scintigraphy with SPECT/CT imaging
has also been shown to be a valid test with a reported
sensitivity of 90% and a specificity of 100% in a cohort
study including 131 patients (25). Another report showed
inconclusive results using the echocardiography in 39
patients with suspected PVE. The results with the use of
18FDG-PET/CT showed a higher sensitivity compared
to SPECT/CT images, but the SPECT had a greater
specificity (26). The ESC 2015 guidelines emphasized the
abnormal meaning of imaging with the use of 18FDGPET /SPECT; a positive sign at the site of a prosthetic
valve (if implanted >3 months previously) is now considered
an important diagnostic criterion for PVE. However, this
criterion is not yet included in the AHA/ACC. Relevant
studies have underlined the fact that the cross-sectional
routine imaging of the brain, chest, spine and viscera can
be diagnostic, and can change the IE management. These
imaging cohort studies suggest that patients with IE have
a high incidence of subclinical complications, such as
hemorrhage, embolism, or abscess. In one prospective study
based on the images of routine cerebral magnetic resonance
(MRI), abnormalities were identified in 80% of patients and
simultaneously ‘upgraded’ 26% (14 of 53 patients) diagnosis
of IE from “possible” to “defined” (27). In another study,
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the use of cerebral angiography CT identified the presence
of intracranial mycotic aneurysms in 32% of patients with
left side endocarditis. Subsequently 50% of them had
endovascular or neurosurgical procedures (28). Iung et al. (29)
revealed anomalies identified in the spleen, liver, or kidneys
for 34% of patients on magnetic resonance imaging of the
abdomen. As a result, evidence of embolism diagnosed
through the transverse imaging is considered as a minor
novel diagnostic criterion in the ESC guidelines 2015 (3).
Since evidence of cross-sectional imaging, be it cardiac
CT and 18FDG-PET or SPECT have the potential to
improve the diagnosis and detection of complications in
patients with suspected IE, it has been incorporated in
routine practice for diagnosis in the subset of patients
termed “Duke possible “and for CDI. However, potential
disadvantages do exist with these modalities. The main
drawback is that metabolic imaging cannot be accurate in
discriminating between barren inflammation and infection,
and is therefore of limited use in the early postoperative
period. The literature reports numerous false positives
for PET/CT imaging after cardiac surgery due to postpericardiotomy syndrome, prosthetic valve thrombosis and
after aortic operation for IE. Two other points to consider
include access to the advanced imaging procedures, which
is often limited, hence when emergency intervention is
required, there is a risk of incurring logistical obstacles that
may delay definitive surgery. The second is related to the
fact that at the moment we are unaware of any randomized
trials that have compared different groups, and it is
unlikely that such a trial will be conducted. Certainly, the
identification of which groups of patients from the clinical
point of view who would benefit the most from advanced
imaging and through which mode it should be precisely
executed remains undetermined (Figure 2).
Routine follow-up imaging
It is agreed that early post-operative imaging is
recommended in all patients who underwent surgery for
IE but the recommendations are incongruent. Followup imaging is recommended at 30 days by ESC (3,5,17),
while 6 weeks to 3 months after valve implantation is
recommended by the ACC/AHA (1,6,8-10), although the
general orientation is to perform an echocardiography
check at the time of hospital discharge. In patients who
have received mechanical valves, the guidelines do not
recommend follow-up imaging for those who are stable
unless there is another indication. In bioprosthetic valve
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Clinical
assessment

Echocardiographic
assessment
TTE/TEE

Precise diagnosis
of IE

Declined
diagnosis of IE

Possible IE
Request for further
imaging for the detection
of complications or
planning to surgery

• Cardiac CT
• CT/MRI

Further diagnostic imaging
• Cardiac CT
• 18F-FDG PET/CT or
SPECT/CT*
• CT/MR cross-sectional imaging
• Repeat TEE

Precise diagnosis
achieved

Figure 2 Show the applied strategy of integrated imaging in patients with suspected infective endocarditis (IE). In patients included in the
subgroup with possible IE after initial evaluation by TTE and TEE a cardiac CT imaging, metabolic imaging or transverse imaging of
the head and viscera by CT scan or MRI is indicated to achieve a precise early diagnosis. For suspected IE a 18FDG-PET/CT or a crosssectional imaging by CT or MRI (or metabolic imaging) scans may assist with detection of complications, such as abscess, mycotic aneurysm,
infarct, or hemorrhage in patients with definite IE. *, 18F-PDG SPECT/CT is useful in patients with prosthetic valves or cardiac implantable
electronic devices. IE, infective endocarditis; CT, computed tomography; 18FDG-PET/CT, 18-fluorodeoxyglucose positron emission; MRI,
magnetic resonance imaging; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; TEE, transoesophageal echocardiography
TTE, transthoracic echocardiography; SPECT, single-photon emission computed tomography.

recipients, who are asymptomatic, routine annual TTE
follow-up imaging is recommended by ESC guidelines (5),
while ACC/AHA guidelines (1,6) recommend annual TTE
only after 10 years from the date of implantation of the
valve. Both guidelines recommend the TTE for the PHV
dysfunction symptoms/signs irrespective of the implant
date and in some patients at higher risk of accelerated
deterioration of the valve even in the absence of symptoms.
The ESC's recommendation is based on a declaration of
consent document (30), following the recommendations
of the Valve Academic Research Consortium-2 (31). In
patients who received conventional stented/non-stented
xenograft, the ACC/AHA recommendation is based on
observations that the incidence of deterioration of structural
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valves is low for bioprosthetic valves in the first 10 years
after implantation.
Antibiotic therapy
For the cardiologist and the surgeon, the main challenges
for the success of the antibiotic therapy are represented by
bacterial tolerance and antibiotic resistance. The persistence
of phenotypic variants of bacteria despite antibiotic therapy
may be the cause of tolerance. The result sees a resumption
of growth and infection once antibiotic concentrations
decrease. The mechanisms involved in tolerance are
manifold, including the high bacterial density and poor
penetration of antibiotics within the vegetations, low
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metabolic bacterial activity and the production of protective
biofilm on the prosthetic material (32). The increase in cases
of Staphylococcus aureus infection has further enhanced
the problem of antibiotic resistance. For this reason, new
strategies should be used to prevent and treat IE caused by
strains that form multidrug-resistant S aureus biofilm. They
are targeted at to the initial bacterial adhesion inhibition
to living and inert surfaces, so as to reduce further the
development of the biofilm. One other action is targeted
at the interruption of the biofilm architecture as well as to
anti-pathogenic approaches or signal interference involving
the inhibition of quorum sensing (33). The prevention
of bacterial adhesion to subsequent insertion of the
intracardiac device deserves particular attention. It is crucial
and can be obtained by using implants coated with various
adhesion inhibitors. Despite antibiotics, ionic silver, and
silver nanoparticle exerting inhibitory actions on biofilm
formation, coated implants were ineffective and poorly
tolerated in humans. The use of monoclonal antibodies
such as TRL1068 has shown some promise with regards to
interrupting the biofilm architecture and is currently under
evaluation. In an in vivo mouse model a biofilm was created
through a resistant methicillin S aureus infection which
was subsequently treated using a combination of TRL1068
with daptomycin. The association of the two products has
significantly reduced the adherent bacteria counts compared
to daptomycin alone (34).
Prolonged antibiotic therapy may lead to toxicity and side
effects to the patients. Therefore, it is necessary to balance
the effectiveness of treatment with the overall risk due to
prolonged antibiotic administration. Emerging evidence
in support of short-term antibiotic treatment is gradually
directed at selected patients. In patients with simple IE
caused by oral streptococci in which renal function is
preserved, a combination of a penicillin or ceftriaxone with
an aminoglycoside for a total of 14 days is indicated and
has been proven to be safe and effective (35). Likewise, a
2-week monotherapy cycle using penicillin or penicillinaminoglycoside in combination demonstrated efficacy
in patients with right-sided IE who were not sensitive to
methicillin (36). The use of aminoglycosides, as growing
data suggest, however, may cause harm without clear
clinical benefits. Fowler et al. (37) in an RCT, compared
the use of daptomycin to conventional therapy (penicillin
or vancomycin with initial gentamicin) in patients with
right side endocarditis sustained by S aureus bacteremia.
Daptomycin has been shown to be non-inferior. The
authors highlighted the occurrence of renal dysfunction
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in 11% of patients in the group treated with daptomycin
compared to 26% of the group that received conventional
therapy (37,38).
The use of aminoglycosides has reduced and they were
removed from guidelines of the AHA/ACC (1,6,8-10)
and ESC (3,5,17) in patients with methicillin-resistant
or methicillin sensitive S aureus NVE. Although
aminoglycosides have gained wide acceptance with
extensive use in the treatment of enterococci IE; however,
the increased frequency of resistance (from 25% to 50%
of isolates in recent studies), alongside the recognition
of the potential harm, prompted the ESC 2015 steering
committee to identify ampicillin and ceftriaxone (class IB
recommendation) as a treatment of choice for Enterococcus
faecalis resistant to aminoglycosides. There are substantial
observational studies in support of this direction that led to
a change in recommendation by the AHA/ACC and ESC.
In these reports it was shown that ampicillin/ceftriaxone
was just as effective with reduced levels of nephrotoxicity
(39,40). Although, current AHA/ACC guidelines (41)
suggest that the remaining duration of antibiotics should
be administered (including administration prior to surgery)
based on level C evidence. However, rationalizing treatment
with antibiotics in patients who have undergone successful
surgery and have negative valve cultures can be considered.
In these patients, the evidence suggests 2 weeks of antibiotic
therapy may be sufficient for eliminating the qualifying
pathogen with a margin of safety (42,43) (Figures 3,4).
New evidence
A benefit towards a rapid transition to oral regimens
of antibiotics with good bioavailability can facilitate a
reduction in hospital stay. Only 1 published RCT POET
(Partial Oral Treatment of Endocarditis) (44) that recruited
400 patients who had endocarditis on the left side of the
heart caused by streptococcus, Enterococcus faecalis,
Staphylococcus aureus, or coagulase-negative staphylococci
compared outcomes between intravenous antibiotics to
continue intravenous treatment (199 patients) or an oral
antibiotic treatment switch (201 patients). The primary
outcome was a composite of all-cause mortality, unplanned
cardiac surgery, embolic events, or relapse of bacteremia
with the primary pathogen, from the time of randomization
until 6 months after antibiotic treatment was completed.
The primary composite outcome was 12.1% in the patients
who received intravenously treatment and 9.0% in those
who were managed with the orally administration of
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First author
Kang et al.
2012

First author
Fowler et al.
2006

Key Findings

Key Findings

In patients with NVE
what is the role of early
surgery within 48 h of
randomization?

Comparison of daptomycin vs.
vancomycin or anti-staphylococcal
penicillin with low-dose gentamicin
for bacteremia or IE caused by
Staphylococcus aureus

Patients Population

Patients Population

Included adult patients
with NVE. Vegetations
located in left-sided, severe
valve disease and large
vegetations

Included adults patients. Presence of
S aureus bacteremia or IE. Excluded
adult patients. Presence of intravascular
material not intended to be removed
within 4 days or high likelihood of valve
replacement surgery or death

First author
Fortun et al.
2001

Key Findings

Key Findings

Does aspirin reduce the
incidence of embolism in
patients with IE?

In patients with right side NVE caused
by methicillin-sensitive S aureus is
effectively a short cycle glycopeptide
(vancomycin or teicoplanin) in
combination with gentamicin as
the combination of cloxacillin and
gentamicin?

Patients Population

Conclusion
In patients with NVE early
surgery reduced the composite
endpoint of in-hospital death
and embolic events within
6 weeks from 23% to 3%
(driven by a reduction in
embolism)

First author
Chan et al.
2003

Conclusion
Daptomycin was noninferior for the
primary endpoint of clinically successful
treatment. Clinically significant renal
dysfunction occurred in 11% of patients
who received daptomycin and in 26% of
patients who received standard therapy
(P=0.004)

Included adults patients with leftsided endocarditis (NVE or PVE).
Excluded adult patients with
expected surgical intervention
within 7 days excluded

Patients Population
Included adult patients with
right-side NVE due to IVDUs
caused by MSSA

Conclusion

Conclusion

Aspirin did not reduce the risk of
embolic events and caused a non
significant trend toward increased
incidence of bleeding

Glycopeptide therapy is
inferior to cloxacillin

Figure 3 Includes 20 yrs 4 RCT of IE published from 2001 to 2012. IE, infective endocarditis; IVDU, intravenous drug user; MSSA,
methicillin-sensitive Staphylococcus aureus; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; RCT, randomized
controlled trial.

antibiotics (3.1 percentage points; 95% confidence interval,
−3.4 to 9.6; P=0.40) showing that oral antibiotic treatment
was non-inferior to continued intravenous antibiotic
treatment (44).
The benefits associated with the use of outpatient
parenteral antibiotic therapy (OPAT) can facilitate early
hospital discharge. OPAT may be initiated in specific
patients after completion of the first 2 weeks of treatment
because the risk of complications is reduced. OPAT
is contraindicated in patients who have heart failure,
complicated infection, high risk of embolism, neurological
complications or renal insufficiency (45-47). Early hospital
discharge is currently being investigated in the ongoing
RCT OPAT (Outpatient Parenteral Antimicrobial Therapy)
with an estimated study completion date of December 31,
2021. The purpose of this study is to investigate the efficacy,
safety and cost effectiveness of treatments administered at
the new OPAT unit of the University Hospital of Lausanne
within the Swiss Health System. The OPAT study recruited
2,000 patients. The primary end point is the efficacy
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classified 3 months after the end of treatment as the absence
of fever and no clinical signs of site infection, readmission
to hospital due to complications related to the infection
and absence of recurrence of the infection within 3 months
post-OPAT.
Finally, the use of ciprofloxacin and rifampicin has
been evaluated in IV drug users (IVDU) with Methicillinresistant S aureus NVE. The RCT data demonstrated safety
and efficacy after oral administration of antibiotics, although
an increase in rates of resistance to fluoroquinolone limited
its applicability (48).
Stroke and IE
Stroke occurs as a complication in 20–50% of cases in
patients with IE (1-3,5). The onset of stroke is a serious
event because besides causing variable disability, it is an
independent adverse prognostic factor for survival (49,50).
Different studies suggest that the risk of stroke is higher at
diagnosis and decreases rapidly after the use of antibiotic
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First author
Ribera et al.
1996

First author
Sexton et al.
1998

Key Findings
Is ceftriaxone plus gentamicin (for
2 weeks) superior to ceftriaxone alone
(for 4 weeks) for IE due to penicillinsensitive streptococci?
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First author
Heldman et al.
1996

Key Findings
Is cloxacillin alone as effective
as cloxacillin plus gentamicin in
a 2-week course for treatment of
right- sided S aureus endocarditis in
IVDUs?

Patients Population
Patients Population

Key Findings
In patients with right-sided staphylococcal
endocarditis due to IVDU is effective oral
administration of ciprofloxacin/rifampicin as
parenteral therapy (oxacillin or vancomycin,
plus gentamicin for the first 5 days)?

Patients Population

Included adult patients with
penicillin-sensitive NVE

Included adult patients with
isolated tricuspid valve
endocarditis due to IVDUs
caused by MSSA.

Included adult patients with
right-sided staphylococcal
endocarditis due to IVDUs

Conclusion

Conclusion

Conclusion

Equivalent clinical cure in both groups

No significant benefit from addition of
gentamicin to cloxacillin (92% cure in
2-week cloxacillin group, 8% required
prolonged treatment)

Oral therapy is as effective as parenteral
treatment and associated with reduced
drug toxicity

Figure 4 Includes 20 yrs 3 RCT of IE published from 1996 to 1998. IVDU, intravenous drug user; MSSA, methicillin-sensitive
Staphylococcus aureus; RCT, randomized controlled trial.

therapy in the initial phase of infection. Dickerman et al. (51)
reported that the incidence of neurological complication
drops from 4.82 per 1,000 patient days in the first week
of therapy to 1.71 per 1,000 patient days in the second
week. Risk factors identified for embolism are the size of
the vegetation (>10–15 mm), the involvement of the mitral
valve, the mobility of the vegetation and S aureus infection.
We have shown that the serious pathological damage
that often occurs in cauliflower-like friable vegetations of
valve leaflets, with or without the extension of the lesion
to the annulus, is an independent factor for embolic
stroke. However, the key unresolved challenge in the
contemporary management of IE, keeping the debate alive
in multidisciplinary heart team decision making, is the
role of surgery in the prevention of stroke/embolism, and
patient selection for choosing the optimal time to surgery.
In the 2015 update of the AHA/ACC guidelines, surgery
is recommended with an indication as Class IIa for surgery
to prevent recurrent embolism in patients with previous
emboli greater ≥10 mm and with high risk of further
embolism. The risk is defined as persistent or enlarged
vegetation (17,41). Similarly for the ESC guidelines the
surgery is categorized as a Class I recommendation, useful
in preventing recurrent emboli in patients with persistent
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vegetation >10 mm in size (3). Surgery is indicated as
a Class IIa recommendation in patients at risk of first
embolism (vegetation >10 mm in size) if associated with
severe valve regurgitation or stenosis. This AHA/ACC and
ESC COR and LOE degree is based on RCT evidence (52).
In patients at high risk of embolism/stroke due to the
presence of vegetations greater than 15 mm, despite the
absence of valve dysfunction, surgery for the prevention
of embolism can be considered. This choice, however, is
rarely undertaken as the sole indication. In patients who
have already had a stroke the optimal timing of surgery
remains a matter of debate, because it is based on a number
of older studies that have reported poor results in patients
who underwent early surgery (53). For these, in fact,
there is a risk of haemorrhagic transformation caused by
anticoagulation during cardiopulmonary bypass, as well as
by hypotension that can intervene during surgery. Both of
these variables can be the cause of theoretical worsening
of cerebral ischemia. Unfortunately, definitive conclusions
cannot be given due to the fact that observational studies
directed towards this topic have generally been small,
inadequately controlled (49,54) and based on unmatched
confounders related to the unmeasurable judgment of the
operating surgeons (2,55-62) (Figures 5,6).
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AHA Guidelines 2015

Heart Failure

Uncontrolled infection

I, B Early surgery* is indicated
in patients with IE who
present with valve dysfunction
resulting in symptoms or
signs of HF I, B Early surgery*
is indicated in patients with
PVE with symptoms or signs
of HF resulting from valve
dehiscence, intracardiac fistula,
or severe prosthetic valve
dysfunction

I, B Early surgery* is indicated in
patients when IE is complicated by
heart block, annular or aortic abscess,
or destructivepenetrating lesions HIa, C
Early surgery* is reasonable for patients
with relapsing PVE
I, B Early surgery* should be considered,
particularly in patients with IE caused by
fungi or highly resistant organisms (e.g.,
VRE, multidrug-resistant gram-negative
bacilli)
I, B Early surgery* is indicated for
evidence of persistent infection
(manifested by persistent bacteremia
or fever lasting >5–7 d, and provided
that other sites of infection and fever
have been excluded) after the start of
appropriate antimicrobial therapy

Prevention of embolism
Ila, B Early surgery* is reasonable in
patients who present with recurrent emboli
and persistent or enlarging vegetations
despite appropriate antibiotic therapy IIa,
B Early surgery* is reasonable in patients
with severe valve regurgitation and mobile
vegetations >10 mm Ib, C Early surgery*
may be considered in patients with mobile
vegetations >10 mm, particularly when
involving the anterior leaflet of the mitral
valve and associated with other relative
indications for surgery

Figure 5 Indications for surgery in AHA. *, defined as “during initial hospitalization and before completion of a full course of antibiotics.”
HF, heart failure; NVE, native valve infective endocarditis; PVE, prosthetic valve infective endocarditis; VRE, vancomycin-resistant
Enterococcus.

New evidence
ICE-PCS collaboration (54) reported the largest series
of 867 patients with IE complicated by ischemic stroke
syndromes and 198 of these who underwent valve
replacement surgery post-stroke. The study evaluated the
effect of 1-year mortality in 58 patients who had early
surgery compared to those (n=147) who received a later
operation. The 58 patients undergoing surgery within
7 days after diagnosis had a trend towards increased inhospital mortality rates than those whose surgery was
managed later (27.1% in early surgery and 19.2% in late
surgery group, P=0.328; adjusted hazard ratio, 1.138; 95%
CI, 0.802–1.650). Based on the interpretation of this result,
the guidelines of AHA/ACC (1,6,41) and ESC (3,5,17)
suggest surgery as an option to be considered if safe,
wherever necessary, although stroke remains a common

© Annals of Translational Medicine. All rights reserved.

reason for avoiding surgery in everyday practice (63). On
the contrary, in the interpretation of the guidelines based
on various studies, the transient ischemic attack or silent
embolism should not delay the indicated surgery for other
reasons (49). This includes instances when the presence of
particularly insidious pathogens for which the diagnosis
can be too late (60). In contrast, patients with cerebral
hemorrhage or complex stroke resulting in a coma have a
significantly higher surgical mortality and surgery should be
postponed for at least 4 weeks if the multidisciplinary heart
team indicates surgery in these patients (63,64). Finally,
the management of patients with minor bleeding or mild
hemorrhagic conversion of an ischemic stroke deserves
consideration. For this category of patients, the clinical
scenario can often be complex and the risk/benefit equation
often challenges any rigid recommendations.
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Surgery
The specific indications for performing surgery in case
of HVE are the presence of progressive damage to the
valve and tissues, uncontrolled infection and high risk of
embolism. Therefore, the first objective of surgery is to
remove the infected tissue and/or the presence of foreign
material; to abolish the threat of embolism sources; to
completely debride the infected paravalvular tissue and any
cavities that are formed; restore cardiac integrity and valve
function. Although the use of various surgical techniques
have been chosen, for example the repair of the mitral valve
or aortic allograft implantation, however, the results have
not yet demonstrated a clear long-term advantage of one
technique over the other. In patients requiring surgery for
an HVE, regardless of which approach is chosen, evidence
has shown that long-term outcomes are inferior than
elective valve surgery. In fact, 10-year survival varies from
40% to 60% (6,65,66) and the choice of the ideal substitute
for HVE surgery remains an open debate (2,55-62,67).
It is not clear whether this delay in mortality refers
to late complications of prosthetic valve, extracardiac
manifestations of the disease, or relapse of infection due
to the persistence of the complex biofilm of the pathogen
responsible for the HVE. In patients with HVE, the use
of surgery is currently performed from 50% to 60% with
reported survival rates at 6 months which are >80% (53,63).
The indications for surgery were mainly based on the
benefits, reported in observational and cohort studies, and
highlighted in patients with valve dysfunction that causes
heart failure, uncontrolled infection or recurrent embolism.
The uncontrolled infection is the condition in which the
infection has had a paravalvular extension, development of
abscess, or persistent bacteremia. The latter, if manifested in
a particular patient, can be reason for discussion in the heart
team shared decision making, when there is mild or relative
heart failure (68). Figures 2 and 3 show the indications for
surgery in accordance with the guidelines of the AHA/
ACC and ESC. It is interesting to note that in real world
situations although there is a significant number of patients
who have a clear indication for surgery in accordance with
the guidelines, surgery is still not performed. In a study by
the ICE-PCS (International Collaboration on EndocarditisPotential Cohort Study) registry, this significant percentage
of patients with left-sided IE, for whom surgical treatment
is required, reaches 24% (202 of 863) (63). As it emerges
from the ICE-PCS registry, many predictive factors
influence the choice to avoid surgery. The avoidance of
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surgery despite HVE was dictated by the presence of liver
disease [odds ratio (OR) for surgery: 0.16; 95% CI: 0.04 to
0.64], infection determined by S aureus (OR: 0.50; 95% CI:
0.30 to 0.85) and stroke before decision to perform surgery
(OR: 0.54; 95% CI: 0.32 to 0.90). Instead the presence
of severe aortic regurgitation, abscess and embolization
was an indication for surgical choice. For 181 patients
who avoided a surgical procedure, the reasons included an
unfavorable early prognosis regardless of treatment (34%),
hemodynamic instability (20%), death before surgery (23%),
stroke (23%), sepsis (21 %) and surgeon’s refusal to operate
(26%). Ultimately, in the study of ICE-PCS group, the
perceived risk of the operation determines the threshold for
surgical treatment. Surgical procedures for active IE present
a high risk, with an overall hospital mortality of 20% which
in many centers can be even higher (63).
New evidence
An important determinant in the choice of surgery in case
of HVE would come from the improvement of the risk
assessment models for IE in order to better clarify the
decision-making process.
The Society of Thoracic Surgeons database was
used to derive a surgical risk score in patients with IE
who were likely to have surgery by Gaca et al. (69). The
model identified 13 risk factors for mortality, including
emergency status, cardiogenic shock, hemodialysis and
active endocarditis. The De Feo et al. (70) and MartínezSellés et al. (71) studies incorporated multiple detailed
parameters of infection, including valve type and organism.
The PALSUSE score included patients aged ≥70 years
and the strong extension of the focus of infection with
substantial intracardiac destruction as risk factors. Other
factors in PALSUSE are as follows: staphylococcus
infection, urgent surgery, female gender and EuroSCORE
(European System for Cardiac Operative Risk Assessment)
value of ≥10 as predictors of mortality in hospital, with inhospital mortality ranging from 0% in patients with a score
of 0, to 45% in patients with a score >3 (71). The optimal
timing of surgery remains a controversial cause for debate.
Advantages and disadvantages are worth considering. On
the one hand, delaying surgery may allow for a longer
duration of antibiotic therapy associated with better
hemodynamic stabilization. Conversely, the postponement
of the surgical procedure can result in the risk of disease
progression with the valve destruction, abscess formation,
heart block, embolic complications and even death. In fact,
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ESC Guidelines
2015

Heart Failure
I, B Emergengy†
Aortic or mitral NVE, or PVE
with severe acute regurgitation,
obstruction, or fistula causing
refractory pulmonary edema or
cardiogenic shock
I, B Urgent†
Aortic or mitral NVE, or PVE
with severe regurgitation or
obstruction causing symptoms of
HF, or echocardiographic signs of
poor hemodynamic tolerance

Uncontrolled infection
I, B Urgent
Locally uncontrolled infection
(abscess, false aneurysm, fistula,
enlarging vegetation) I, C Urgent/
Elective Infection caused by fungi or
multiresistant organisms IIa, B Urgent
Persisting positive blood cultures
despite appropriate antibiotic therapy
and adequate control of septic
metastatic foci IIa, C Urgent/Elective
PVE caused by staphylococci or nonHACEK gram-negative bacteria

Prevention of embolism
I, B Urgent
Aortic or mitral NVE, or PVE with persistent
vegetations > 10 mm after 1 embolic episode
despite appropriate antibiotic therapy IIa, B
Urgent Aortic or mitral NVE with vegetations
>10 mm, associated with severe valve
stenosis or regurgitation, and low operative
risk Hla, B Urgent Aortic or mitral NVE, or
PVE with isolated very large vegetations
(>30 mm) IIb, C Urgent Aortic or mitral NVE,
or PVE with isolated large vegetations
(>15 mm) and no other indication for surgery

Figure 6 Indications for surgery in ESC. †, defined as: emergency surgery = performed within 24 h; urgent surgery = within a few days;
elective surgery = after at least 1 to 2 weeks of antibiotic therapy. HACEK, Haemophilus species, Aggregatibacter species, Cardiobacterium
hominis, Eikenella corrodens, and Kingella species; HF, heart failure; NVE, native valve infective endocarditis; PVE, prosthetic valve
infective endocarditis; VRE, vancomycin-resistant Enterococcus.

for some outcomes such as embolism, the potential gains of
the surgery are reduced over time (51). In 2012, in a pivotal
Korean RCT (52), HVE surgery was randomized to early
surgery (performed within 48 hours of randomization)
and conventional care in patients with NVE, severe valve
regurgitation and large vegetations. The patient population
included in the study reported by Kang et al. (52) were
young (average age 47 years), with few comorbidities and
predominantly streptococcal infection. In the results it was
shown that early surgery was associated with a significant
reduction in the composite endpoint of death or hospital
embolism. In addition, surgery was required for more
than 90% of patients receiving conventional care, thus
validating indications for surgery. This study is a point of
reference for the strategy to be applied in HVE and has
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encouraged a trend towards early surgery. However, the
results found in the study are limited and its applicability is
uncertain in older populations with multiple comorbidities
and staphylococcal infection. The findings of the Korean
study (52) conflict with the results of the studies from
the ICE-PCS registry (51), which define early surgery as
being undertaken “during the initial hospitalization for
IE”. Although early surgery for patients with NVE was
associated with reduced mortality, this was not true for
patients with PVE after adjusting for confounding variables
(55,57).
Cardiac surgeons are faced with a different interpretation
of the emergency/urgency criterion expressed
in the international guidelines. The emphasis on “early
surgery” differs significantly between European and US

Ann Transl Med 2020;8(23):1623 | http://dx.doi.org/10.21037/atm-20-3739

Annals of Translational Medicine, Vol 8, No 23 December 2020

guidelines. The ESC guidelines (3,5,17) distinguishes
emergency surgery (performed within 24 hours), urgent
surgery (within a few days) and elective surgery (after
1–2 weeks of antibiotic therapy), restricting to patients in
whom urgent surgery is recommended for most cases. On
the contrary, the AHA guidelines (1,6,8,9,41) define early
surgery as “during the initial hospitalization and before
completion of a full course of antibiotics.” Based on our
experience and considering many reports we can conclude
that there are no proven benefits in delaying surgery
once an indication for surgery has been established. The
choice of timing for the surgery between the same day of
hospitalization/diagnosis or 48 hours from hospitalization
for HVE depends on the individual clinical circumstance
and availability of adequate surgical skills (2,55-62,67,72).
The current series have shown that it is possible to obtain
very low mortality in centers of excellence with high
level experience in managing complex patients where
the different skills bring together experts in cardiology,
microbiology and surgery (60). The controversy that
emerges in the management of the patient with HVE that
requires the choice of early surgery can only be resolved
through solid tests that advance the field. RCT level data
is needed to guide change of practice because data from
observational studies may lack robustness. Based on these,
it is more difficult to progress because there is concern
that observational/cohort studies may be biased in favor of
conventional mechanical or stented xenograft prosthesis
by unmatched confounders related to the personal
consideration of the engaging surgeons (55-59). As can be
seen from Figure 4 in the last 20 years, only 7 randomized
studies involving IE patients have been published, most of
primarily focused on antibiotic therapy and only one on the
optimal time for the surgical procedure (52).
The solution to this conundrum would be to carefully
define the priorities for new RCTs. They must be
reasonable and acceptable to the medical community.
Multicenter studies are demanding and may be limited
to concerns regarding becoming outliers as experience
and results vary widely between centers. However, the
advantage of multicenter registry studies is in the very large
volume of patients participating, as few centers have the
volume to perform these studies individually. Furthermore,
unresolved issues, such as early surgery, may be side-lined
due to competing/divergent research. This is clearly evident
in patients with PVE. Should they be clustered with the
other patients in indications for surgery? Is it recommended
that all patients with IE and severe valve dysfunction
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undergo surgery, even if they do not have heart failure?
Finally, as proposed by San Román et al. (68), a randomized
clinical trial of patients with left-sided IE and high-risk
characteristics, but without classic surgical indications,
would be useful. Enrolment groups should include those
receiving surgery within 48 hours or patients destined for
conventional care, with mortality as the primary endpoint.
Although logistically demanding, this study would not only
be of widespread interest but would be valuable and could
announce the long-awaited transition from observational
studies to RCT-level research (56-59).
Conclusions
We have noted several differences between guidelines
of the AHA/ACC recommendations regarding the
management of patients with HVE. The existence of
non-binding recommendations on guidelines seem
contradictory, especially if indicative for important
decisions such as the optimal timing of surgical treatment.
We have also found that a small number of observational
studies were cited by both guidelines, although supporting
opposite recommendations. The lack of high-quality
evidence for the management of patients with HVE is
not only obvious but is restricted to the management of
patients who are often in severe clinical conditions. The
short-term goal would be to increase randomized trials
for these patients because in their absence, questions
regarding the validity of these recommendations will
remain topics of discussion.
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